ACBD7

Across TCGA pan-cancer cohorts, ACBD7 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ACBD7 data layer compared with 27 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ACBD7 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ACBD7 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

PDAC, GBM, and UCEC are the cancer types where ACBD7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.316	0.618	.006	12	view →
GBM	OS	Median	All	0.659	0.421	.013	11	view →
UCEC	OS	Tertile	All	0.838	0.972	.024	2	view →
LSCC	DFS	Median	II,III,IV	0.856	1.000	.031	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ACBD7–PDAC (OS)

Open the PDAC breakdown →